Prognostic value of [18F]FDG- and PSMA-PET in patients evaluated for [177Lu]Lu-PSMA therapy of mCRPC
Tuğçe Telli(Essen University Hospital), Wolfgang P. Fendler(Essen University Hospital), Robert Seifert(University Hospital Münster), Leonor Lopes(University Hospital of Bern), Lale Umutlu(Essen University Hospital), Kim M. Pabst(West German Heart and Vascular Center Essen), Claudia Kesch(Essen University Hospital), Kuangyu Shi(University of Bern), Ken Herrmann(Essen University Hospital), Viktor Grünwald(Deutsche Schmerzgesellschaft), Madeleine J. Karpinski(Deutsches Konsortium für Translationale Krebsforschung), Boris Hadaschik(Essen University Hospital)
Cited by 9
Related Papers
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial
|The Lancet Oncology|2017|431
Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial
|The Lancet Oncology|2016|219
Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities
|Clinical Cancer Research|2022|145
Non-invasive tumor decoding and phenotyping of cerebral gliomas utilizing multiparametric 18F-FET PET-MRI and MR Fingerprinting
|European Journal of Nuclear Medicine and Molecular Imaging|2019|131
Growth Hormone and Sex Steroid Effects on Bone Metabolism and Bone Mineral Density in Healthy Aged Women and Men
|The Journals of Gerontology Series A|2002|91